Fresenius medical care delivers on commitments in a year of fundamental transformation

Revenue growth of 5% in 2023 driven by favorable business development operating income1 growth of 15% exceeding top end of outlook range, due to business growth, fme25 savings ahead of plan and contributions from the tricare settlement successful execution on turnaround plan resulting in significant labor productivity improvements in care delivery and positive pricing in care enablement several key divestments announced as part of the ongoing portfolio optimization program strong cash flow performance and net financial leverage ratio reduced dividend of €1.19 per share proposed for 2024 continued revenue growth and accelerated operating income growth projected bad homburg, germany, feb. 20, 2024 /prnewswire/ -- helen giza, chief executive officer of fresenius medical care, said: "in 2023, we delivered on our commitments while we fundamentally transformed fresenius medical care. exceeding our upgraded financial outlook for the full year was the very successful finish to an extraordinary year.
FMS Ratings Summary
FMS Quant Ranking